DSN LINK STABLECARRIER WAVE LOCKORBITAL INDEX HOTSIGNAL CLOCK SYNCLOW NOISE FLOORFRAME BUFFER ONLINE
Loading
DSN LINK STABLECARRIER WAVE LOCKORBITAL INDEX HOTSIGNAL CLOCK SYNCLOW NOISE FLOORFRAME BUFFER ONLINE
Loading portal core
115 articles
Ocrelizumab significantly slowed disability progression in a major international Phase III trial of primary progressive multiple sclerosis, including older patients and people with more advanced disease.
A dental implant is not just a passive screw in bone once peri-implantitis develops: a new report suggests titanium particles may be part of the reason antibiotics often fail.
SMILE-FX Orthodontic Studio in Miramar has introduced AI Braces as a local, data-informed attempt to make orthodontic planning more predictable before teeth begin to move.
A medical chatbot that confidently invents an answer is not just a weak product; it is a real safety risk.
Oura no longer wants to be only a ring for sleep and recovery: according to STAT, it is entering a crowded race to measure blood pressure without a traditional cuff.
An experimental gene-editing drug cut LDL cholesterol by 62 percent after a single dose in a small trial, but proof of effect is not yet proof of broad safety.
LASIK still has no true successor, but a new electrical cornea-reshaping method shows what vision correction could look like without lasers, scalpels, or permanent tissue removal.
Drug safety in pregnancy still often rests on incomplete evidence, and machine learning is now being tested as a way to pull review-worthy signals faster from data that already exist.
BioVAT is not yet a practice-changing therapy, but it goes directly at heart failure’s hardest problem: lost myocardium that does not simply grow back.
Colon cancer screening is no longer framed only around colonoscopy and stool tests: ACS now brings newer FDA-approved molecular options, including blood tests, into its guidance.
Kailera's 'triple-G' story sounds like another strike in the obesity-drug race, but for now the missing details matter more than the headline.
Stanford Health Care is trying to move health AI review out of the technical back room and into a space where patients can say what is acceptable before a tool becomes part of care.
The FDA’s de novo clearance for Modius is not just another wearable-device headline, but a regulatory signal that neuromodulation is moving deeper into PTSD care.
Investigational ecopipam reduced relapse risk versus placebo in children and adolescents with Tourette syndrome in a phase III randomized withdrawal study.
Early data from a Utah pilot puts AI prescription renewal exactly where it is most sensitive: between routine administration and real clinical responsibility.
Trustworthy clinical AI is not a demo problem; it is an evidence-after-deployment problem.
Wearable sensors already measure the body in motion, but without robust data science and clinical validation they remain sophisticated signal sources, not therapeutic instruments.
In rare disease trials, statistics cannot rescue a poorly chosen endpoint: if the COA misses what actually changes, the treatment signal can disappear into noise.
AI in pharmaceutical R&D is no longer just a molecule-search tool, but an attempt to turn biology into a design system that still has to pass reality’s exam.
AI can accelerate parts of therapeutic antibody design, but BigHat Biosciences’ interview makes clear it is not a magic passage through the costliest and riskiest stages of drug development.
The problem with pulse oximeters is not one number on a screen, but the way that number can decide who gets attention, follow-up testing and faster care.
The FDA has expanded treatment options for one of the hardest newly diagnosed AML groups: older and clinically frailer adults for whom intensive induction chemotherapy is not a realistic route.
More than 400,000 Reddit posts were turned into an early signal radar for GLP-1 drug side effects, showing how patient forums can surface what formal trials may not catch early enough.
Wegovy, one of the most visible weight-loss drugs on the market, is now under fresh scrutiny over a rare eye event that can end in sudden vision loss.
Topical ABT-263 accelerated wound closure in aged mice and boosted gene signals tied to collagen production and tissue regeneration.
CAR T therapy, one of modern oncology’s most aggressive tools, is now being tested in autoimmune disease, where the target is no longer a tumor but an immune system attacking its own body.
Houston Methodist has used a personalized mRNA vaccine in a patient with osteosarcoma in an attempt to reduce relapse risk under FDA compassionate use.
Varda Space Industries has signed a deal with United Therapeutics that could turn microgravity into a real production line for drugs.
Research published in JAMA Network Open links psilocybin plus psychotherapy with more cocaine-free days in people with cocaine use disorder.
The Johns Hopkins approach lowers the intensity of bone-marrow transplant conditioning, a crucial difference for patients who may not tolerate the standard path.
A University of South Florida study shows PanPep performs well in the lab but much worse in realistic immune-response scenarios.
Automated evaluation can scale safety checks, but it must not pretend to be diagnosis.
A breast cancer study mapped 78 paired tumors and metastases, showing how metabolically reprogrammed cells suppress immune response in lymph nodes.
Concordia's robot can find a cardiac ultrasound window, but patients are still the next hurdle.
Brown University researchers found 15 ethical risks when large language models are used as mental health counselors.
Sixian You's team published their counterintuitive finding in Nature Methods on April 28.
Forty-two β-thalassaemia patients in a Milan-led trial stopped needing blood transfusions after CRISPR edited their *BCL11A* gene to boost fetal hemoglobin.
Replika’s user base now includes 1.2 million people who tell it ‘I love you’ daily—yet the company employs exactly zero licensed therapists.
A study in *EMBO Molecular Medicine* links MDGA1 gene mutations to autism’s male bias, marking a step toward biological clarity—but no treatment yet.
Researchers at and collaborators mapped 350,000+ cells across early and late pregnancy stages to build the first of the maternal-fetal interface.
MD Anderson’s team pinpointed immune signatures in Lynch Syndrome patients’ blood—yet the study’s lack of sample details leaves clinicians skeptical.
IB101’s defined binding pocket marks a structural advance, but the compound has yet to enter preclinical testing.
The New York Times profile of Medvi omitted a critical detail: proof that the '$1.8 billion' telehealth startup was anything more than smoke and mirrors.
The article 'Minimal life by computer' presents a significant step forward in the development of virtual cells, with a focus on uniting AI's pattern-finding power with mechanistic models.
Lab-grown *Tyrannosaurus rex* protein now costs less to produce than it did five years ago—though ‘less’ still means thousands per square inch.
UCLA scientists have developed a simple and cost-effective blood test that shows promise in detecting multiple cancers, various liver conditions, and organ abnormalities simultaneously.
The Salton Sea's environment affects children's lung function growth, with significant implications for public health policy.
Apple’s Studio Display XDR is now the first consumer monitor FDA-cleared for primary diagnostic imaging—a validation previously reserved for $10,000+ medical-grade screens.
The largest randomized trial of its kind found a computational method for assessing coronary blockages matched invasive testing in 92% of cases—yet regulators and clinicians aren’t ready to call it a replacement.
Chengpeng Mou’s leaked ChatGPT stats expose a healthcare system so fractured that 70% of AI medical queries happen when no human doctor is on call.
A single investor just turned $1 million into $385 million—without a drug, a trial, or even a double-digit headcount.
Cambridge chemists turned a botched reaction into a method that uses LED light to edit drug molecules—no toxic solvents required.
Researchers have identified a small molecule that can prevent kidney stone formation in a rare genetic disorder.
Swedish researchers exploited hemoproteins like hemoglobin to polymerize conductive n-PBDF directly in brain tissue, sidestepping traditional fabrication barriers.
The FDA’s silence on Kintsugi’s depression-detecting AI spoke louder than any algorithm—so the startup folded after seven years and open-sourced its tech.
Researchers documented zero major complications in pediatric patients undergoing SEEG-guided thermocoagulation—a rare bright spot in drug-resistant epilepsy treatment.
Epia Neuro’s neural implant doesn’t just assist stroke-damaged hands—it attempts to reprogram the brain’s motor cortex while a robotic glove forces the limb through lost movements.
STAT News analysis reveals the FDA’s ‘breakthrough’ AI devices lean toward broad-impact solutions over niche tools.
The April 2026 *Nature Medicine* editorial doesn’t just call health information important—it classifies unequal access as a *structural determinant of health*, a category previously reserved for factors like income or pollution.
Keratinocytes in the epidermis don’t just detect threats—they broadcast them via a newly identified pathway, Chinese researchers revealed in *Nature Immunology* this week.
Nearly a dozen personalized cancer vaccine platforms are now in human trials, but none have cleared regulatory approval.
OpenAI’s GPT-4 aced a simulated bar exam with a 90th-percentile score—then in real court filings.
A single compromised repository at CareCloud now forces 45,000+ providers to confront the same question: what patient data might be in the wrong hands?
A 16-week trial across 13 countries just gave pediatric cardiologists their first phase 3 data on mavacamten for obstructive HCM in youth.
T cells—immune system’s off-meta pick—just outplayed antibodies in a *Cell Reports* study, targeting viral ‘core files’ instead of mutable cosmetics.
Chongjie Zhang’s team at WashU has taught robots to learn from each other’s goals, not just their code.
Microsoft and Amazon’s new AI health tools process patient data at scale—but neither has cleared FDA validation for clinical use.
Insilico Medicine’s AI platform has never produced an FDA-approved drug—but Eli Lilly just wagered up to $2.75 billion on its potential.
Dr. James White, MD, found a clear benefit to using the 4D model to target treatment for CRT patients.
The FDA’s involvement marks Whoop’s first serious attempt to shift from luxury fitness tracker to medical device.
CVS faces a settlement over manipulated insulin prices, potentially saving Americans $7 billion.
AstraZeneca's in vivo CAR-T therapy has shown early responses in 50% of patients, according to Endpoints News.
The hunt for Parkinson’s disease mechanisms just got a new lead: a cellular ‘overflow valve’ that, when broken, may let toxins accumulate.
A British clinical trial participant has controlled *World of Warcraft* for 100 days using only his thoughts—but the data is still just one patient deep.
Telmisartan, an FDA-approved blood pressure drug, has been found to enhance the cancer-killing activity of olaparib, according to a study led by Tyler J. Curiel, MD, MPH, FACP.
When parasitic worms invade the gut, the body’s response goes beyond local inflammation.
Denali's Surnazyme treats Hunter syndrome in under 2,000 global patients.
Xaira's X-Cell model is the largest virtual cell model to-date, with 1 million parameters, according to the company's press release.
IB101’s defined binding pocket marks a structural advance, but the compound has yet to enter preclinical testing.
Penn’s AI didn’t just train on 300,000 MRI clips—it sidestepped a $1B contrast-agent industry to do it.
Researchers from UIC have made a significant breakthrough in the treatment of drug-resistant herpes, using an FDA-approved cancer drug, doxorubicin, to target the virus.
New blueprint aims to accelerate approvals for rare pediatric gene therapies.
In vivo CAR-T trials show promise, skipping lab processing.
Tirzepatide + hormone therapy yields 35% more weight loss for women over 50.
Gamers know the drill: a flashy trailer drops, promises the moon, and six months later you’re staring at a buggy mess with half the features cut.
Triangle Health’s $4 million round arrives as the FDA tightens rules on AI-driven medical advice tools.
Researchers at MIT modified lipid nanoparticles with aromatic compounds.
IB101’s defined binding pocket marks a structural advance, but the compound has yet to enter preclinical testing.
Neuralink’s first public gaming demo proves brain implants can handle complex inputs—but reliability remains untested.
BIIB094’s phase 1 trial marks the first time an antisense oligonucleotide has successfully targeted LRRK2 in Parkinson’s patients.
Researchers have developed stitches that release anti-inflammatory drugs for weeks, but the technology is years from clinical use.
For the 537 million adults living with diabetes worldwide, the ritual of daily insulin injections is a reminder of medicine’s stubborn limits.
The ethical and scientific quagmire of animal testing may have a new contender: genetically engineered, brainless organ systems.
Novartis drops $3B on SNV4818, a PI3Kα inhibitor claiming pan-mutant coverage—where alpelisib’s toxicity and modest efficacy leave room for a rival.
Roche’s breast cancer pill persevERA flunks crucial Phase 3 trial, costing the pharma giant its blockbuster hopes worth billions.
A study in *GEN News* identifies tunneling nanotubes as a key pathway for mutant huntingtin protein transfer in brain cells.
A recent study published in Nature Medicine has found that a deep learning model using smartwatch data can predict peak oxygen uptake and unplanned healthcare events in patients with heart failure.
A *Nature Biotechnology* review published this March outlines the first coherent vision for AI that could unify genomics, protein folding, and synthetic biology under one model.
A first-in-class antimalarial drug candidate, MK7602, has demonstrated human tolerance in early clinical studies, though its efficacy remains unproven.
Lab-grown CAR T cells bypass external editing—preclinical success against 3 cancers, a major leap for solid tumors.
Xaira Therapeutics has launched X-Cell, an AI model for virtual cell simulation, accompanied by a 57-page technical paper.
The first public user of an invasive brain-computer interface will demonstrate Neuralink's chip to a professional audience, but the real measure of success happens when the cameras go dark.
A breakthrough noninvasive method measures beta cell mass in living patients—potentially rewriting type 1 diabetes treatment strategies.
Lecanemab, a key Alzheimer's drug, has been found to activate immune cells through the Fc fragment of the antibody, according to researchers.
A semaglutide-bimagrumab combo in phase 2 preserved nearly all lean mass while cutting fat dramatically.
A breast cancer study mapped 78 paired tumors and metastases, showing how metabolically reprogrammed cells suppress immune response in lymph nodes.
Zorevunersen reduced seizures by up to 91 percent in early trials involving children with Dravet syndrome.
Kobe University's system needs only two photos: dorsal hand view and clenched fist.
Obesity treatment may have just taken a measured step forward.
Brown University researchers found 15 ethical risks when large language models are used as mental health counselors.
